



OncoDefender™-CRC Patient FAQ

1. OncoDefender™-CRC is the world's only molecular prognostic test which is capable of accurately predicting the risk of recurrence of cancer in patients previously treated with surgical resection of a Stage I and Stage II colon cancer tumor or Stage I rectal cancer tumor. No other currently available molecular prognostic test approaches the performance capabilities of OncoDefender-CRC in this regard.
2. Patients identified by OncoDefender-CRC at high-risk of cancer recurrence may benefit from adjuvant therapy or other more aggressive treatment options.
 - a. Independent studies¹ have demonstrated a significant improvement in overall survival rates for high-risk Stage I and Stage II colorectal cancer patients receiving adjuvant therapy within 60 days following surgical resection of their tumor.
3. The OncoDefender-CRC test will help you and your physician make appropriate post-surgical decisions about the need for adjuvant therapy.
4. Regardless of your insurance coverage or financial status, the Everist Genomics Customer Support team will assist you in obtaining the testing you need. Everist Genomics will help you verify whether or not your insurance covers the test and will bill the insurance company (or Medicare) on your behalf. In the unlikely event that your insurance company denies coverage, or if you require financial assistance, Everist Genomics also has a generous financial assistance program. Qualifying patients are eligible to have up to 80% of the cost of the OncoDefender-CRC test covered through one of the Everist Genomic Financial Assistance programs.

¹ Gastrointestinal Cancers Symposium, Source reference: Biagi JJ et al. "Time to adjuvant chemotherapy in colorectal cancer: Systematic review and meta-analysis" *ASCO GI* 2011; Abstract 364; Bayraktar UD, Chen E, Bayraktar S, Sands LR, Marchetti F, Montero AJ, Rocha-Lima CM. Does delay of adjuvant chemotherapy impact survival in patients with resected stage II and III colon adenocarcinoma? *Cancer*. 2010 Dec 17.; *J Clin Oncol*. 2010 Jan 20;28(3):460-5. Epub 2009 Dec 14. Association between disease-free survival and overall survival when survival is prolonged after recurrence in patients receiving cytotoxic adjuvant therapy for colon cancer: simulations based on the 20,800 patient ACCENT data set. de Gramont A, Hubbard J, Shi Q, O'Connell MJ, Buyse M, Benedetti J, Bot B, O'Callaghan C, Yothers G, Goldberg RM, Blanke CD, Benson A, Deng Q, Alberts SR, Andre T, Wolmark N, Grothey A, Sargent D. Hopital Saint Antoine, Group Hospitalier Pitie-Salpetriere, Paris, France; et. Al.

1. What is the OncoDefender-CRC test?

The OncoDefender-CRC test is a gene-based laboratory test intended to help guide treatment decisions following surgery to remove Stage I/II colon or Stage I rectal cancer. The test examines a number of genes that have been linked to predicting the growth and progression of colorectal cancer and will help determine the likelihood of your cancer returning (recurrence). The OncoDefender-CRC test will help you and your physician make appropriate post-surgical decisions about the need for additional preventative chemotherapy or other more aggressive treatment options.

2. How accurate is OncoDefender-CRC?

OncoDefender-CRC is the world's only molecular prognostic test which is capable of accurately predicting the risk of recurrence of cancer in patients previously treated with surgical resection of a Stage I and Stage II colon cancer tumor or Stage I rectal cancer tumor. No other currently available molecular prognostic test approaches the performance capabilities of OncoDefender-CRC in this regard.

According to an independent statistical review, test results correlate well with accurately predicting colorectal cancer recurrence. In studies, the test performs better than other methods currently available to predict recurrence.

As with any test, you and your physician should discuss the results and interpretation of the OncoDefender-CRC test as they relate to any other treatment you are undergoing or tests you may have had previously.

3. Why should I consider OncoDefender-CRC?

Patients identified by OncoDefender-CRC at high-risk of cancer recurrence may benefit from additional preventative chemotherapy (also referred to as 'adjuvant therapy') or other more aggressive treatment options. Independent studies have demonstrated a significant improvement in overall survival rates for high-risk patients receiving adjuvant therapy within 60 days following surgical resection of their tumor.

OncoDefender-CRC is a colorectal cancer prognostic tool that, when combined with existing screening and detection methods, will assist your physician in deciding if additional potentially beneficial therapy (adjuvant therapy) is recommended following initial surgery to remove your tumor.

4. What is the difference between a prognostic test and a diagnostic test?

A prognostic test is used to indicate the future course of the disease and the risk of recurrence whereas a diagnostic test is performed to aid in the initial detection and diagnosis of disease.

5. I had a family member die of colorectal cancer. Can OncoDefender-CRC help me and others in my family?

Consult with your physician about your specific risk of colorectal cancer recurrence so that they can determine what risk screening program is best for you. OncoDefender-CRC can only determine if you are likely to recur after the primary tumor is surgically resected. The test does not predict the risk of someone initially developing colorectal cancer. We have provided additional information for physicians on our web site to help them determine how OncoDefender-CRC may be used in the clinical management of patients.

6. How often should I get an OncoDefender-CRC test?

OncoDefender-CRC is a prognostic (predictive) tool that uses tumor tissue obtained at the time of surgery for Stage I/II colon cancer and Stage I rectal cancer. The results of this one-time test are used by you and your physician to help decide what the most appropriate post-operative clinical management strategy is for you, including whether or not you should receive chemotherapy.

7. Who developed OncoDefender-CRC?

The OncoDefender-CRC technology is derived from research and development by Everist Genomics, based in Ann Arbor, MI. Everist Genomics was formed in 2002 and is privately owned.

8. How do I order OncoDefender-CRC?

Consult with your oncologist or surgeon about ordering the test for you. You may also refer to "How to Order an OncoDefender-CRC Test" on our web site for details on ordering through Everist Genomics' laboratory services. If your doctor has questions before ordering or does not have access to the information on our web site, please contact us, and we will send the requested background information.

9. Is the cost of OncoDefender-CRC reimbursed by insurance?

Regardless of insurance coverage or financial status, the Everist Genomics Customer Support team will assist you in obtaining the testing you need. We will help you verify whether or not your insurance covers the test and will bill the insurance company on your behalf. In the unlikely event that your insurance company denies coverage, or if you require financial assistance, Everist Genomics also has a generous financial assistance program. Qualifying patients are eligible to have up to 80% of the cost of the OncoDefender-CRC test covered through one of the Everist Genomic Financial Assistance programs. Within 3 to 4 working days of receiving your completed application for testing, Everist Genomics will provide you and your doctor with written confirmation of your financial benefits as well as how to proceed.

10. Is OncoDefender-CRC certified in any way?

Yes. Everist Genomics' central laboratory is a clinical reference laboratory that is regulated by the Clinical Laboratory Improvement Amendments (CLIA). These federally regulated standards, adopted by Congress in 1988, were developed to ensure the accuracy, reliability and timeliness of all clinical laboratory results in the United States. The effectiveness of OncoDefender-CRC has been statistically and scientifically validated through clinical research studies conducted by Everist Genomics.

11. Who will see the results of my OncoDefender-CRC test?

Your OncoDefender-CRC test results, along with all patient and physician information, are held in the strictest confidence by Everist Genomics and in accordance with the guidelines of the federal Health Insurance Portability and Accountability Act (HIPAA) of 1996. Results from your test will be sent only to the doctors specified on the test order form by the ordering clinic or physician's office.

12. What information is reported from the OncoDefender-CRC test and how long does it take to get the results?

The OncoDefender-CRC test report includes an assessment of the risk for cancer recurrence within 3 years of your surgery (resection). Typically, OncoDefender-CRC results are reported within 10 business days from receipt of your sample and test requisition form.

13. Can I use the results of OncoDefender-CRC to delay or cancel any other treatment?

No. The OncoDefender-CRC is a prognostic tool and should be used in conjunction with all the other treatment, screening, and detection tools at your physician's disposal. All of these tools, combined with the OncoDefender-CRC test, should be utilized following your physician's recommendation.

14. Is OncoDefender-CRC a genetic test?

While OncoDefender-CRC does measure certain gene expression levels, it is not a test for hereditary or genetic predisposition of any disease or disorder. In this test, certain gene expression values are combined mathematically in a unique way to produce a relative measure of risk of recurrence, but an actual analysis of your genetic information is not specifically reported.

15. Where can I get additional information?

For more information about Everist Genomics, please visit www.EveristGenomics.com. For more information about colorectal cancer and other resources available on the web, please visit:

- [American Cancer Society](#)
- [National Cancer Institute - Colon and Rectal Cancer](#)
- [National Human Genome Research Institute - Learning about colon cancer](#)
- [MedicineNet](#)
- [Prevent Cancer Foundation](#)
- [Association of Community Cancer Centers](#)
- [Cancer.net](#)
- [CancerCare](#)
- [Patient Access Network Foundation](#)
- [Centers for Disease Control and Prevention](#)
- [National Colorectal Cancer Roundtable](#)